

**Brookings Council on Antibacterial Drug Development Meeting #1**

The Brookings Institution • Washington, DC

Thursday, August 30, 2012

**Participant List**

**Paul Ambrose**

President, Institute for Clinical  
Pharmacodynamics and Honorary Research  
Professor, University of Oxford College of  
Medicine

**Danny Benjamin**

Professor of Pediatrics and Faculty Associate  
Director, Duke Clinical Research Institute, Duke  
University School of Medicine

**John Bradley**

Professor and Chief, Division of Infectious  
Diseases, Department of Pediatrics, University of  
California, San Diego, School of Medicine and  
Director, Division of Infectious Diseases, Rady  
Children's Hospital San Diego

**Robert Califf**

Vice Chancellor for Clinical and Translational  
Research, Director of the Duke Translational  
Medicine Institute, Duke University Medical  
Center

**Deborah Collyar**

President, Patient Advocates In Research

**Heather Colvin**

Senior Research Associate, Engelberg Center for  
Health Care Reform, The Brookings Institution

**Allan Coukell**

Director, Medical Programs, Pew Health Group,  
The Pew Charitable Trusts

**Edward Cox**

Director, Office of Antimicrobial Products,  
Center for Drug Evaluation and Research,  
U.S. Food and Drug Administration

**Ralph D'Agostino**

Chairman, Mathematics and Statistics  
Department, and Professor of  
Mathematics/Statistics, Biostatistics, and  
Epidemiology, Boston University

**Gregory Daniel**

Managing Director and Fellow, Engelberg Center  
for Health Care Reform, The Brookings Institution

**Robert Danner**

Senior Investigator and Head, Infectious Diseases  
Section, Critical Care Medicine Department,  
National Institutes of Health Clinical Center

**Dennis M. Dixon**

Chief, Bacteriology and Mycology Branch,  
National Institute of Allergy and Infectious  
Disease, National Institutes of Health

**Mike Dudley**

Senior Vice President, Research & Development  
and Chief Scientific Officer, Rempex  
Pharmaceuticals, Inc.

**Michael Dunne**

Chief Medical Officer, Durata Therapeutics

**Barry Eisenstein**

Senior Vice President of Scientific Affairs, Cubist  
Pharmaceuticals and Clinical Professor of  
Medicine, Harvard Medical School

**John Farley**

Deputy Director, Office of Antimicrobial Products,  
Center for Drug Evaluation and Research, U.S.  
Food and Drug Administration

**Thomas Fleming**

Professor, Department of Biostatistics,  
University of Washington School of Public Health

**Vance Fowler Jr.**

Professor, Department of Medicine – Infectious  
Diseases, Duke University

**David Friedland**

Vice President, Clinical Sciences, Cerexa, Inc.

**David N. Gilbert**

Chief of Infectious Diseases and Director, Earle A. Chiles Research Institute, Providence Portland Medical Center and Professor of Medicine, Oregon Health and Sciences University

**Mark Goldberger**

Divisional Vice President, Regulatory Policy and Intelligence, Abbott Pharmaceuticals

**Mohammad Huque**

Director, Division of Biometrics IV, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Dmitri Iarikov**

Medical Officer, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Audrey Jackson**

Senior Program Officer, Science and Research, Infectious Diseases Society of America

**John Jenkins**

Director, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Larry Kocot**

Deputy Director, Engelberg Center for Health Care Reform, Visiting Fellow, Economic Studies, The Brookings Institution

**Katie Laessig**

Deputy Director, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Joe Larsen**

Chief, Broad Spectrum Antimicrobials (BSA) Program, Division of CBRN Medical Countermeasures, Biomedical Advanced Research and Development Authority

**Lisa LaVange**

Director, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Dara Lieberman**

Senior Government Relations Manager, Trust for America's Health

**Ben Lorenz**

Medical Officer, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Mark McClellan**

Director, Engelberg Center for Health Care Reform, Senior Fellow, Economic Studies, and Leonard D. Schaeffer Chair in Health Policy Studies, The Brookings Institution

**Kunal Merchant**

Senior Clinical Project Manager, Clinical Trials Transformation Initiative

**Bob Meyer**

Vice President, Global Regulatory Strategy, Policy and Safety, Merck

**Theresa Mullin**

Director, Office of Planning and Informatics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Sumati Nambiar**

Deputy Director for Safety, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Kevin Outtersen**

Associate Professor of Health Law, Bioethics and Human Rights, Boston University School of Law

**John Powers**

Senior Medical Scientist, Science Applications International Corporation in support of the National Institute of Allergy and Infectious Diseases, National Institutes of Health and Associate Clinical Professor of Medicine, George Washington University School of Medicine

**Charlene Reed**

Founder and Chief Executive Officer, Foundation to Combat Antimicrobial Resistance

**John Rex**

Infection Clinical Vice President, AstraZeneca Pharmaceuticals and Adjunct Professor of Medicine, University of Texas Medical School at Houston

**Kellie Schoolar Reynolds**

Deputy Division Director, Division of Clinical Pharmacology IV, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Louis Rice**

Chair, Department of Medicine, Warren Alpert Medical School of Brown University and Physician-in-Chief, Rhode Island Hospital and The Miriam Hospital

**Melissa Robb**

Associate Director for Regulatory Affairs, Office of Medical Policy Initiatives, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Leonard Sacks**

Associate Director for Clinical Methodology, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Jonas Santiago**

Analyst, Division of Medical Policy Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Rachel Sherman**

Director, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**David Shlaes**

Sole Proprietor and President, Anti-Infectives Consulting

**Tom Smith**

Lead Medical Officer, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Brad Spellberg**

Associate Professor of Medicine, Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

**George Talbot**

Principal, Talbot Advisors LLC

**Bob Temple**

Deputy Center Director for Clinical Science and Acting Deputy Director of the Office of Drug Evaluation I (ODE-I), Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Pamela Tenaerts**

Executive Director, Clinical Trials Transformation Initiative

**Jeanine Thomas**

President and Founder, MRSA Survivors Network

**Joe Toerner**

Associate Director for Medical Affairs, Office of Antimicrobial Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**John Tomayko**

Senior Medical Director, GlaxoSmithKline

**Janet Woodcock**

Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration